Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Capital Expenditures: 2013-2019

Historic Capital Expenditures for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2019 value amounting to $5,000.

  • Soleno Therapeutics' Capital Expenditures rose 150.00% to $5,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $23,000, marking a year-over-year decrease of 96.01%. This contributed to the annual value of $218,000 for FY2024, which is N/A change from last year.
  • Soleno Therapeutics' Capital Expenditures amounted to $5,000 in Q4 2019, which was down 16.67% from $6,000 recorded in Q2 2019.
  • Soleno Therapeutics' Capital Expenditures' 5-year high stood at $570,000 during Q3 2017, with a 5-year trough of -$244,223 in Q4 2015.
  • For the 3-year period, Soleno Therapeutics' Capital Expenditures averaged around $75,125, with its median value being $5,000 (2019).
  • Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Capital Expenditures was 28,400.00% (2017), while the steepest drop was 200.00% (2017).
  • Soleno Therapeutics' Capital Expenditures (Quarterly) stood at -$244,223 in 2015, then spiked by 97.05% to -$7,205 in 2016, then surged by 28,400.00% to $570,000 in 2017, then crashed by 99.12% to $2,000 in 2018, then spiked by 150.00% to $5,000 in 2019.
  • Its Capital Expenditures stands at $5,000 for Q4 2019, versus $6,000 for Q2 2019 and $10,000 for Q1 2019.